NCT01897740No Longer Available不适用
A LOCAL, SINGLE-CENTRE, EXTENSION, OPEN LABEL ACCESS STUDY, TO PROVIDE SILDENAFIL THERAPY FOR SUBJECTS WHO COMPLETED A1481156 STUDY AND ARE JUDGED BY THE INVESTIGATOR TO DERIVE CLINICAL BENEFIT FROM CONTINUED TREATMENT WITH SILDENAFIL, PRIOR TO REIMBURSEMENT AND AVAILABILITY FOR SUBJECTS IN RUSSIAN FEDERATION
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家开始时间: 2013年7月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildenafil, prior to reimbursement and availability for subjects in the Russian Federation.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 10 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and Availability for Subjects in Russian Federation.
- •Child bearing age women should have appropriate contraception.
- •Signed informed consent. Patients who have a wish and possibility to follow treatment regimens in terms of the study.
排除标准
- •Pregnant and lactating women.
- •Participation in other studies in the current moment or during study period except of A
- •Patients with severe acute or chronic diseases psychiatric disorders or laboratory abnormalities.
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Local Open-Label Access Study For Patients Who Completed A1481244 Study In BrazilPulmonary Arterial HypertensionNCT00866983Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
No Longer Available
不适用
An Open Label Access Study For Subjects Who Completed A1481156Pulmonary Arterial HypertensionNCT01582438Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
已完成
不适用
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 WeeksPulmonary HypertensionNCT00946114Pfizer's Upjohn has merged with Mylan to form Viatris Inc.32
已完成
4 期
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early EveningAdult Attention Deficit Hyperactivity DisorderNCT06000501NYU Langone Health29
No Longer Available
不适用
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNon-Small Cell Lung CancerNCT02271139Genentech, Inc.